(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 25.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Bioage Labs's earnings in 2025 is N/A.On average, 3 Wall Street analysts forecast BIOA's earnings for 2025 to be -$78,271,386, with the lowest BIOA earnings forecast at -$104,682,108, and the highest BIOA earnings forecast at -$51,982,554. On average, 3 Wall Street analysts forecast BIOA's earnings for 2026 to be -$79,110,277, with the lowest BIOA earnings forecast at -$108,984,112, and the highest BIOA earnings forecast at -$42,661,544.
In 2027, BIOA is forecast to generate -$81,139,389 in earnings, with the lowest earnings forecast at -$104,323,608 and the highest earnings forecast at -$50,907,053.